Chemotherapy News and Research

Latest Chemotherapy News and Research

Biothera's Phase II clinical trials in lung cancer attain stage 1 endpoint

Biothera announced today that its second Phase II non-small cell lung cancer trial, evaluating Imprime PGG® in combination with bevacizumab (Avastin®) and two chemotherapeutic agents, has achieved its stage 1 endpoint and has begun enrolling patients for stage 2 of the study.

20 Apr 2011

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of results from the first human phase 2 study of masitinib carried-out in the treatment of Alzheimer's disease.

20 Apr 2011

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Genentech, a member of the Roche Group and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

20 Apr 2011

Mount Sinai's new Dubin Breast Center to provide patients with seamless care

The new Dubin Breast Center of The Tisch Cancer Institute at Mount Sinai opened today, bringing a range of multidisciplinary services under one roof and marking a great leap forward in care of breast cancer patients throughout the region.

19 Apr 2011

Seattle enters second ADC research collaboration agreement with Genmab

Genmab A/S and Seattle Genetics, Inc. announced today that the companies have entered into a second antibody-drug conjugate research collaboration agreement.

19 Apr 2011

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the publication of a case report in the peer-reviewed Journal of Clinical Oncology documenting the use of tamibarotene in the successful treatment of a patient with recurrent advanced-stage acute promyelocytic leukemia.

19 Apr 2011

Bedford Labs launches cancer drug Topotecan Hydrochloride for Injection

Bedford Laboratories, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Topotecan Hydrochloride for Injection, 4 mg (base)/vial to its diverse portfolio. Topotecan is AP Bioequivalent to the reference listed drug Hycamtin® (topotecan HCl) for injection by GlaxoSmithKline.

19 Apr 2011

Biotech Synergy concludes EP-2101 asset transfer, cancer epitopes related portfolio

Biotech Synergy has concluded the asset transfer of multi-epitope cancer vaccine product formerly known as EP-2101 and cancer epitopes related portfolio. Emile Loria, M.D., former President and Chief Business Officer of IDM and former President & CEO of Epimmune, is the founder of Biotech Synergy.

18 Apr 2011

Novocure's NovoTTF-100A System receives FDA approval for GBM treatment

Novocure today announced that the U.S. Food and Drug Administration approved the NovoTTF-100A System for the treatment of adult patients with glioblastoma multiforme brain tumors, following tumor recurrence after receiving chemotherapy.

16 Apr 2011

NVP-BEZ235 inhibits growth of ovarian cancer cells, increases survival: Study

An experimental drug that blocks two points of a crucial cancer cell signaling pathway inhibits the growth of ovarian cancer cells and significantly increases survival in an ovarian cancer mouse model, a study at UCLA's Jonsson Comprehensive Cancer Center has found.

16 Apr 2011

Data of ImmunoCellular's lead dendritic cell cancer vaccine candidate for GBM presented at AAN meeting

ImmunoCellular Therapeutics, Ltd., announced that Surasak Phuphanich, MD, Principal Investigator of the Phase I clinical trial of ImmunoCellular's lead dendritic cell cancer vaccine candidate for glioblastoma multiforme presented safety and preliminary efficacy data yesterday at the American Academy of Neurology 63rd Annual Meeting.

16 Apr 2011

Novocure receives FDA approval for NovoTTF-100A System to treat GBM

The U.S. Food and Drug Administration recently approved the NovoTTF-100A System, a new device to treat adults with glioblastoma multiforme that recurs or progresses after receiving chemotherapy and radiation therapy.

15 Apr 2011

FEN1 enzyme might serve as anti-cancer therapy target

An enzyme essential for DNA replication and repair in humans works in a way that might be exploited as anti-cancer therapy, say researchers at The Scripps Research Institute and Lawrence Berkeley National Laboratory.

15 Apr 2011

Researchers pinpoint new approach that can treat pediatric leukemia

A Loyola University Health System study points to a promising new approach to treating an aggressive and usually fatal leukemia in babies.

15 Apr 2011

Quest PharmaTech, Hemispherx Biopharma enter clinical development arrangement

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced a clinical development arrangement with U.S. based Hemispherx Biopharma Inc. to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune activator in a thirty patient clinical trial.

15 Apr 2011

EPO grants patent to OncoGenex OGX-427 for prostate cancer treatment

OncoGenex Pharmaceuticals, Inc., today announced that the European Patent Office has granted European Patent Number EP1545561 entitled "Oligonucleotides for Treatment of Prostate and other Cancers."

15 Apr 2011

Catherine Zeta Jones treated for bipolar disorder

Catherine Zeta Jones – the 41-year-old Welsh actor checked into a day clinic in Connecticut for five days earlier this month for the treatment of bipolar disorder. “After dealing with the stress of the past year, Catherine made the decision to check in to a mental health facility for a brief stay to treat her Bipolar II Disorder,” said publicist Cece Yorke said in a statement adding, “She's feeling great and looking forward to starting work this week on her two upcoming films.”

13 Apr 2011

Hypericin may treat recurrent malignant brain tumors

Researchers have found that a synthetic version of hypericin, a compound naturally found in St. John's wort, may be a promising treatment for patients with recurrent malignant brain tumors. Their findings were published online on March 31, 2011 in the journal Cancer.

12 Apr 2011

Strong bitter taste can cause nausea: Research

Swallow the good, spit out the bad. A new study from the Monell Center highlights the vital role taste plays as the body's gatekeeper. The research shows that strong bitter taste in and of itself can cause people to both report the sensation of nausea and display a pattern of stomach activity characteristic of actual nausea.

12 Apr 2011

Novelos Therapeutics acquires Cellectar

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that it has completed its acquisition of Cellectar, Inc., a Wisconsin-based drug development company, in a stock-for-stock transaction.

12 Apr 2011